Theorem Clinical Research

R&D Trends

Trovagene, Genomac expand collaboration

Wednesday, January 21, 2015 12:57 PM

Trovagene, a provider of technology for the detection and monitoring of cell-free DNA headquartered in San Diego, will expand its clinical collaboration with Genomac Research Institute in Prague, Czech Republic. Trovagene Precision Cancer Monitoring technology will be used in two prospective clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies used to treat colorectal and lung cancer.

More... »

Quest Diagnostics

Johnson & Johnson forms Ebola vaccine development consortia

Monday, January 19, 2015 12:48 PM

Johnson & Johnson has formed a consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than $116 million from the Ebola+ program to support the development, manufacturing and patient education for the vaccine regimen.

More... »


Neuropore, UCB enter world-wide collaboration and agreement

Monday, January 19, 2015 12:45 PM

Neuropore Therapies, a wholly owned U.S. subsidiary of Austria-based Ever Neuro Pharma, and UCB, a Brussels, Belgium-based global biopharmaceutical company, have entered into a worldwide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease and related disorders. This includes NPT200-11, Neuropore’s novel small molecule that targets pathogenic alpha-synuclein, which currently is in preclinical development and is expected to enter clinical phase I in 2015.

More... »

AC Immune, Janssen to collaborate on Alzheimer's disease vaccines

Friday, January 16, 2015 12:29 PM

AC Immune, a Swiss-based biopharmaceutical company, has entered into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals to develop and commercialize therapeutic anti-Tau vaccines for the treatment of Alzheimer's disease and potentially other tauopathies.

More... »

Report: Innovation driving positive outlook for pharma and biotech in 2015

Friday, January 16, 2015 12:28 PM

Innovation will continue to drive the pharma and biotech sectors in 2015 as forecasts point to another prosperous year, according to EP Vantage’s latest report, Pharma & Biotech 2015 Preview. EP Vantage is the editorial arm of global market intelligence firm Evaluate.

More... »

MRIGlobal awarded $54M by NIH

Friday, January 16, 2015 12:25 PM

MRIGlobal, an independent, nonprofit CRO based in Kansas City, Mo., has been awarded a $54 million, 10-year program from the National Institute of Neurological Disorders and Stroke to provide support for the development and manufacturing of drug candidates for ultimate use in human clinical trials.

More... »

35 partners from industry and academia collaborate on European research initiative

Thursday, January 15, 2015 01:40 PM

The European Prevention of Alzheimer's Dementia (EPAD) initiative has begun a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.

More... »

Oncology and infectious diseases forecast as top investment areas for 2015

Thursday, January 15, 2015 01:39 PM

Oncology, cardiovascular, autoimmune/anti-inflammatories and infectious diseases will be the top areas of investments in 2015, according to a report by global growth consulting firm Frost & Sullivan.

More... »

Report: Turkish life sciences industry draws outside investors, pharma

Thursday, January 15, 2015 01:36 PM

Big pharmaceutical companies and foreign investors are flocking to Turkey to capitalize on its encouraging economic policies, according to global growth consulting firm Frost & Sullivan. The establishment of technology development zones that exempt pharmaceutical entrepreneurs and academics from income taxes until 2023 has played a particularly crucial role in driving R&D activity in the life sciences industry.

More... »

Moderna, Merck to develop messenger RNA-based antiviral vaccines

Wednesday, January 14, 2015 12:41 PM

Moderna Therapeutics has announced a license and collaboration agreement with Merck, through a subsidiary, for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). Moderna’s work in the collaboration will be led by Valera, its venture focused on the development of mRNA vaccines and therapeutics to fight infectious disease. Moderna is privately held, Cambridge, Mass.-based company founded by Flagship VentureLabs.

More... »

AiCure
CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs